Interview with: Andrew Baum, President and CEO - featuring: their biopharmaceuticals and non-pharmaceutical products based on its plant genetic engineering skills and proprietary oilbody-oleosin technology platform - the Stratosome™ Biologics System, with insulin and a developmental cardiovascular drug called Apo AI, as their 2 lead pharmaceutical product candidates. |
|
| SemBioSys Genetics Inc. (SBS-TSX) |
|
|
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
This is a printer friendly page! SemBioSys’ technology platform allows them to produce
proteins in plants and to extract and purify those proteins inexpensively for use in
treating cardiovascular and metabolic diseases, such as atherosclerosis and diabetes
|
|
“We were happy to announce recently, that we have achieved commercial levels of insulin expression in safflower. What that means is that we now have safflower plants, which we use to produce our proteins, that are producing enough insulin to make our process extremely cost-effective, the ability to reduce cost of goods about 40% or more, capital costs about 70% or more and offering an unparallel degree of flexibility. It is important to note that this was a major de-risking element for the insulin program in that the biggest concern that we had was biological; could the plants accumulate enough insulin to make our process economical. Other people have tried and failed, we succeeded. The balance of our development process is mainly execution, it is within our control, and we are very good at execution in this company. Our next milestone is getting insulin into the clinic in 2007; we believe that using an abbreviated 505 (b) (2) clinical trial, we could be in the market as early as late 2009 or 2010.” - Andrew Baum |
|
